November 13, 2025Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T-Cell Engagers Utilizing SAFEbody® TechnologyView Press Release
March 13, 2025Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive CancersView Press Release
July 23, 2024Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) DiseasesView Press Release